anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Parkinson's disease (PD) is a neurodegenerative disease whose pathogenic mechanism is the degeneration of substantia nigra of the midbrain, causing the degeneration of dopaminergic neurons in the putamen and caudate nucleus of the striatum, and the dopamine content in the synapses decreases and gradually loses the ability to act. Most of the clinical symptoms are motor function defects. The most obvious symptoms are tremor, limb stiffness, motor dysfunction and gait abnormality, and cognitive and behavioral problems may occur. In nuclear medicine PET examinations, labeled radiopharmaceuticals are possible to enter the putamen and caudate nucleus regions of the striatum in the brain by intravenous injection. The severity of Parkinson's disease is assessed and diagnosed by quantitative analysis of the defect in the image of the radiopharmaceuticals. Clinical studies often use manual selection of regions of interest (ROIs) for quantitative analysis. However, this method causes human error and low reproducibility due to subjective factors, and also considerable time consuming. Therefore, in order to solve the above problems, this research project plans to build an automated quantitative analysis system for PET/MRI images. The quantitative analysis of the PET images is performed automatically by using the putamen and caudate ROI segmented by the MRI images. In this study, patients will perform MRI T1 and 18F-FDOPA PET scanning of before and after acupuncture-treated PD patients in VGHTPE PET/MRI scanner. Every patient will be administered 185 MBq (5 mCi) of 18F-FDOPA by IV injection. The MRI image is used to extract the target and background ROIs (region of interests), and is coregistered to the PET image. The ROIs generated by MRI image will be applied to its corresponding PET image. Then, specific uptake ratio (SUR) will be calculated for each patient. The calculation of SUR is the difference between the average image pixel value of the target ROI (left and right striatum) and the average image pixel value of the background ROI (occipital lobe) divided by the average value of the background ROI. After calculated each patients' standard uptake ration, Asymmetry index (ASI) can be calculated based on the absolute difference of SUR value of both sides (left and right) of striatum, divided by average SUR value of both sides of striatum. This automated quantitative analysis system is expected to improve the time-consuming, low reproducibility, and subjectivity problems of traditional manual ROI selection method, and provide a useful tool for the diagnosis of early PD. In the first year, this sub-project is expected to perform MRI T1 and 18F-FDOPA PET scanning of before and after acupuncture-treated PD patients provided by sub-project 3. In the second year, the correlation analysis will be made with the results of tremor test provided by sub-project 1 and that of the 99mTc-TRODAT SPECT image quantification provided by sub-project 4.
Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial "itching" sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS.
Problem: To provide a pharmaceutical composition for prevention or treatment of urinary track organ cancer. The composition does not cause a problem with respect to side effects, can be continually used for an extended period of time, and is administered to a urinary track organ by injection into a cavity of the urinary track organ. Solution: a solution configured to be injected into a cavity of a urinary track organ, the solution containing D-allose. The urinary track organ cavity is inside the upper urinary tract and inside the bladder. The solution is for injection therapy where the solution is injected into a cavity of a urinary track organ, and for utilization of increase in D-allose sugar intake into urinary track organ cancer cells (e.g. RT112, 253J, J82). The solution contains D-allose together with a pharmaceutically acceptable dilution agent or support. This pharmaceutical composition is for prevention or treatment of cancers in a urinary track organ.
Compositions for treatment of the skin are prepared by mixing with an oily or unguentous carrier an organic peroxidic or ozonidic compound. Acidic peroxides such as benzoyl, salicyl peroxides and the peroxides of butyric, lactic, caprylic, lauric, palmitic, stearic, phenylacetic, chaulmoorgric and "hydrocarpic" acids are suitable and also the derivatives of corresponding anhydrides, salts or esters. Peroxides of alcohols, esters, ketones, ethers and aldehydes may also be used. Mild oxygen splitting catalysts may be added.  Vehicles containing lanolin, spermaceti, beeswax, soaps, vegetable, animal and mineral oils, higher fatty acids, zinc oxide, boric acid, borax, gum tragacanth, gum acacia, and essential oils are suitable.  The compositions may be used as ointments, nasal sprays and toothpastes.
OBJECTIVE: To evaluate the olfactory acuity and quality of life in patients who have undergone total laryngectomy. The study also aims to identify any specific patient-related risk factors linked to worse olfactory outcomes.
METHODS: This is a prospective cross-sectional study conducted at the University Malaya Medical Centre. A total of 30 patients who have undergone total laryngectomy were assessed objectively using the Sniffin' Sticks test and compared against normal age-matched Malaysians. Subsequently, they also filled out the modified Questionnaire on Olfactory Disorders. Correlations of patient demographics, disease and treatment variables against olfactory outcomes were conducted.
RESULTS: All subjects suffered olfactory impairment, with 66.7% of them being anosmic after total laryngectomy. The Sniffin' Sticks test demonstrated a statistically significant difference between laryngectomees and the normal age-matched Malaysian population in all three subtests for odor threshold, discrimination and identification. 37% of patients developed olfactory adaptive methods, which resulted in higher olfactory scores and a better quality of life. There were no patient demographics, disease or treatment variables associated with a poorer olfactory outcome identified.
CONCLUSION: Olfactory impairment should not be overlooked among patients after total laryngectomy. Although as many as a third of patients developed some sort of olfactory adaptive behavior, early rehabilitation should be integrated into the multidisciplinary rehabilitation program after total laryngectomy.
The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
OBJECTIVES: Chemokines are inflammatory mediators directly involved in immunological mechanisms that mediate alloimmune responses; recently, gene expression analysis studies have aroused great interest in the field of transplantation. We aimed to evaluate the predictive role of chemokine gene expression in rejection in renal transplant patients.
MATERIALS AND METHODS: Our study included 91 patients who underwent living-related renal transplant. Gene expression levels of chemokines were evaluated in urine samples collected preoperatively and postoperatively. Patients were followed up frequently in the clinic, and the relationship between chemokine levels and the development of acute rejection was investigated.
RESULTS: The CXCL11 and CXCL13 gene expression levels at day 1 (P = .018 and P = .037), day 7 (P = .021 and P = .041), and month 1 (P = .039 and P = .039) after renal transplant were significantly higher in patients with acute rejection. CCL2 gene expression level was significantly higher in the group with acute rejection on day 1 (P = .038) and day 7 (P = .014) posttransplant. CCL5 expression level was higher in the group with acute rejection only on day 7 posttransplant (P = .027).
CONCLUSIONS: Follow-up of allograft function after renal transplant is of utmost importance. CXCL11, CXCL13, CCL2, and CCL5 gene expression levels may have roles in immune monitoring as they seem to have a potential to predict rejection.
The invention concerns immunogens, immunogenic compositions and method for the treatment of gastrin-dependent tumors. The immunogens comprise a gastrin receptor immunomimic peptide conjugated to an immunogenic carrier. The immunogens are capable of inducing antibodies in vivo which bind to the gastrin-receptor (GR) in gastrin responsive malignant or premalignant tumor, thereby preventing growth stimulating peptide hormones from binding to the receptors, and inhibiting tumor cell growth. The invention also comprises specific antibodies against the gastrin-receptor for passive immunization. Furthermore, the invention comprises cytotoxic molecule derivatized anti-GR antibodies. The invention also concerns diagnostic methods for detecting gastrin-dependent tumors in vivo or from a tissue biopsy using the antibodies of the invention. Active and passive immunization can be combined providing an immune response against GR, G17 and/or G17-Gly.
<P>PROBLEM TO BE SOLVED: To provide a tyrosinase activity inhibitor and/or a lipoxygenase activity inhibitor derived from a natural plant Alpinia speciosa and having high safety and to provide a medicine, a cosmetic or a food preserving agent as uses thereof.  <P>SOLUTION: The tyrosinase or/and lipoxygenase activity inhibitors comprise an extract from the Alpinia speciosa, especially an extract from a rhizome of the Alpinia speciosa as an active ingredient. An external preparation for skin and the cosmetic are obtained by formulating the inhibitors. A therapeutic agent for inflammatory diseases is prepared by formulating the inhibitor having lipoxygenase activity inhibitory actions. The food preserving agent is obtained by formulating the inhibitors having the tyrosinase or/and lipoxygenase activity inhibitory actions.  <P>COPYRIGHT: (C)2008,JPO&INPIT
High HBV DNA levels predispose to mother to child transmission (MTCT) of HBV. Early nucleotide analogue (NA) therapy can reduce HBV DNA and minimize MTCT. We analysed immune-metabolic profile in pregnant mothers who received NA from 2nd trimester compared with untreated mothers. In 2nd trimester, there was no difference in immune profiles between Gr.1 and Gr.2 but high viral load women had downregulated pyruvate, NAD+ metabolism but in 3rd trimester, Gr.1 had significant reduction in HBV-DNA, upregulated pyruvate and NAD with increased IFN-2αA, CD8Tcells, NK cells and decreased Tregs, IL15, IL18, IL29, TGFβ3 compared to Gr.2. In Gr.1, three eAg-ve women showed undetectable DNA and HBsAg. At delivery, Gr.1 showed no MTCT, with undetectable HBV DNA, HBsAg, high CD8 and NK cells in two women. We conclude, that starting NA from second trimester, reduces HBV load and MTCT, modulates NAD, induces immunity and suggest use of NA in early gestation in future trials.
<P>PROBLEM TO BE SOLVED: To provide pharmacists whom patients rely on, and pharmacies enabling the patients to obtain health information.  <P>SOLUTION: A pharmacy video on demand medicine and health information distribution system enables pharmacies to select expert packages comprising daily medical care, health information, etc. per medical department and to request distribution of the expert packages and causes a distribution source to create and distribute expert packages as packages for the pharmacies so as to enable patients to view contents selected by them any time and transmits the number of times of accesses for use of each content in a certain period, to the distribution source and causes the distribution source to reorganize and redistribute the packages in accordance with ranking of the number of times of use. The pharmacy video on demand medicine and health information distribution system enables patients to obtain the latest medical care and health care information and information on medicines, healthy foods, and their prescriptions, etc. on demand and includes the latest medicine information for pharmacists which promotes communication between patients and pharmacists.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Vaccination with 2x10\^8 PFU MVA-MERS-S_DF1. Vaccinations will be administered at days 0, 28 or 56, and 336.
Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
The invention relates to medicine. A hardware/software system for the rehabilitation of patients with cognitive impairments of the upper extremities after stroke comprises a virtual reality glove, a controller with a sensor, an encephalograph, and a computer with specialized cognitive games installed thereon. The glove is configured with built-in sensing elements that allow the movement of a patient's fingers and hand to be tracked in space. The controller is positioned on the shoulder joint in order to collect information about the movements of the shoulder joint during the execution of exercises in the games. The computer is configured to be capable of receiving information from the aforementioned devices; performing a computerized analysis of the information received regarding the patient's brain, arm muscle and fine motor skill function; determining the patient's fatigue level; automatically adjusting the exercises in the games and selecting the most effective exercises; and storing patient rehabilitation results in a database. The invention provides for more effective rehabilitation of patients with cognitive impairments of the upper extremities after stroke.
BACKGROUNDS: Blood-brain barrier (BBB) disruption after intracerebral hemorrhage (ICH) significantly induces neurological impairment. Previous studies showed that HDAC6 knockdown or TubA can protect the TNF-induced endothelial dysfunction. However, the role of HDAC6 inhibition on ICH-induced BBB disruption remains unknown.
METHODS: Hemin-induced human brain microvascular endothelial cells (HBMECs) and collagenase-induced rats were employed to investigated the underlying impact of the HDAC6 inhibition in BBB lesion and neuronal dysfunction after ICH.
RESULTS: We found a significant decrease in acetylated α-tubulin during early phase of ICH. Both 25 or 40 mg/kg of TubA could relieve neurological deficits, perihematomal cell apoptosis, and ipsilateral brain edema in ICH animal model. TubA or specific siRNA of HDAC6 inhibited apoptosis and reduced the endothelial permeability of HBMECs. HDAC6 inhibition rescued the degradation of TJ proteins and repaired TJs collapses after ICH induction. Finally, the results suggested that the protective effects on BBB after ICH induction were exerted via upregulating the acetylated α-tubulin and reducing stress fiber formation.
CONCLUSIONS: Inhibition of HDAC6 expression showed beneficial effects against BBB disruption after experimental ICH, which suggested that HDAC6 could be a novel and promising target for ICH treatment.
The thermal grill illusion (TGI), a phenomenon in which the juxtaposition of innocuous warm and cold temperatures on the skin elicits a burning sensation, offers a unique perspective to how pain occurs in response to harmless stimuli. We investigated the role of the spinal cord in the generation of the TGI across 2 experiments (total n = 80). We applied heat and cold stimuli to dermatomes, areas of skin innervated by a single spinal nerve, that mapped onto adjacent or nonadjacent spinal segments. Enhanced warm and burning ratings during the TGI were observed when cold and warm stimuli were confined within the same dermatome. Furthermore, we found the spatial organisation of warm and cold stimuli within and across dermatomes affected TGI perception. Perceived warmth and burning intensity increased when the cold stimulus projected to the segment more caudal to the warm stimulus, whereas perceived cold during the TGI decreased compared with the opposite spatial arrangement. This suggests that the perception of TGI is enhanced when cold afferents are projected to spinal segments positioned caudally in relation to those receiving warm afferents. Our results indicate distinct interaction of sensory pathways based on the segmental arrangement of afferent fibres and are consistent with current interpretations of the spread and integration of thermosensory information along the spinal cord.
The proportion of lung cancer in never smokers is rising, especially among Asian women, but there is no effective early detection tool. Here, we developed a polygenic risk score (PRS), which may help to identify the population with higher risk of lung cancer in never-smoking women. We first performed a large GWAS meta-analysis (8595 cases and 8275 controls) to systematically identify the susceptibility loci for lung cancer in never-smoking Asian women and then generated a PRS using GWAS datasets. Furthermore, we evaluated the utility and effectiveness of PRS in an independent Chinese prospective cohort comprising 55 266 individuals. The GWAS meta-analysis identified eight known loci and a novel locus (5q11.2) at the genome-wide statistical significance level of P < 5 × 10-8 . Based on the summary statistics of GWAS, we derived a polygenic risk score including 21 variants (PRS-21) for lung cancer in never-smoking women. Furthermore, PRS-21 had a hazard ratio (HR) per SD of 1.29 (95% CI = 1.18-1.41) in the prospective cohort. Compared with participants who had a low genetic risk, those with an intermediate (HR = 1.32, 95% CI: 1.00-1.72) and high (HR = 2.09, 95% CI: 1.56-2.80) genetic risk had a significantly higher risk of incident lung cancer. The addition of PRS-21 to the conventional risk model yielded a modest significant improvement in AUC (0.697 to 0.711) and net reclassification improvement (24.2%). The GWAS-derived PRS-21 significantly improves the risk stratification and prediction accuracy for incident lung cancer in never-smoking Asian women, demonstrating the potential for identification of high-risk individuals and early screening.
High-fat diet (HFD)-induced dyslipidemia is frequently accompanied by gut microbiota dysbiosis and a compromised gut barrier. Enhancing the intestinal barrier function emerges as a potential therapeutic approach for dyslipidemia. The ILC3-IL22-IL22R pathway, which responds to dietary and microbial signals, has not only attracted attention for its crucial role in maintaining the intestinal barrier, but recent reports have also suggested its potential in regulating lipid metabolism. Limonin is derived from the Chinese herb Evodiae fructus, which has shown potential in ameliorating dysbiosis of serum lipids. However, its underlying mechanisms remain elusive. Consequently, targeting the ILC3-IL22-IL22R pathway to enhance intestinal barrier function holds promise as a therapeutic approach for dyslipidemia. In this study, male C57BL/6 mice were subjected to a 16-week HFD to induce dyslipidemia and concurrently administered oral limonin. We discovered that limonin supplementation dramatically reduced serum lipid profiles in HFD-fed mice, significantly curbing HFD-induced weight gain and epididymal fat accumulation. Ileal histopathological evaluation indicated limonin's ameliorative effects on HFD-induced intestinal barrier impairment. Limonin also moderated the intestinal microbiota dysbiosis, which is characterized by the elevation of Firmicutes in HFD mice, and notably amplified the abundance of probiotic Lactobacillus. In addition, supported by flow cytometry and other analyses, we observed that limonin upregulated the ILC3-IL22-IL22R pathway, enhancing phosphorylated STAT3 (pSTAT3) in intestinal epithelial cells (IECs), thereby reducing lipid transporter expression. In conclusion, our study revealed that limonin exerted a promising preventive effect against HFD-induced dyslipidemia by the mitigation of the intestinal barrier function and intestinal microbiota, and its mechanism was related to the upregulation of the ILC3-IL22-IL22R pathway.
The invention discloses a triangular prism-shaped nano-silver composite probe with a stable structure, and a preparation method and application thereof, and belongs to the technical field of nano biological materials. The triangular prism-shaped nano silver composite probe with the stable structure is of a core-shell structure, the surface of the triangular prism-shaped nano silver probe is modified by alkyl acid containing sulfydryl to form an inner core, and the shell is polydopamine. The preparation method takes the silver nanoprism as a core, modifies the alkyl acid containing sulfydryl, and takes the polydopamine as a shell to form a core-shell structure. Preferably, the targeting polypeptide is modified to simultaneously load chemotherapeutic drugs. The probe can effectively avoid the degradation of the nano silver prism and has high stability. After the target polypeptide is modified and the chemotherapeutic drug is loaded, the target polypeptide can be well gathered at the tumor part, and the chemotherapeutic drug can be rapidly released, so that the combined treatment of photo-thermal treatment and chemotherapy is realized. The probe can also be used for ultrasonic photoacoustic imaging and tomography imaging. The probe and PD1 are combined for treatment, and the effect of inhibiting cancer metastasis is very remarkable.
<P>PROBLEM TO BE SOLVED: To preliminarily prevent the occurrence of any mistake concerning injection to be performed by visiting a patient's living room.  <P>SOLUTION: A PDA 8 is configured as a portable terminal for inputting/outputting information associated with medical actions. A server 7 is configured to transfer the information with the PDA 8. An in-hospital information managing system 2 manages the execution schedule of operations associated with medical actions to be performed to a patient. In this hospital information system 1, patient identification information applied to the patient for identifying the patient and container identification information applied to a container into which injection liquid to be given to the patient by injection to be executed to the patient is imparted for identifying the container are collated with instructions associated with the injection to the patient, and when the result of the collation is reasonable, the contents of the instructions are outputted from the PDA 8.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.